ASH Clinical Practice Guidelines
ASH Guidelines are developed by leading clinical, methodological, and patient experts through a rigorous process to review evidence and write actionable recommendations. Our state-of-the-art methodology ensures that they meet the highest standards for trustworthiness and transparency. Guideline panels are explicit about how recommendations were determined and open about the quality of evidence that factored into the final decision-making process.
Browse the existing guidelines below, and learn about guidelines currently in development, including those open for public comment. Additional resources, including pocket guides, are available for select guidelines.
Guideline Topics
Two ASH Clinical Practice Guidelines published in 2026 cover the treatment of Acute Lymphoblastic Leukemia in Adolescents and Young Adults. Pocket guides are available for this topic.
Guidelines covering the treatment of acute myeloid leukemia in older adults. These guidelines update and augment the ASH AML guidelines published in 2025. Pocket guides are available for this topic.
Guidelines providing evidence-based recommendations to facilitate early and accurate diagnosis of AL amyloidosis were published in 2026. A second panel covering the treatment of AL amyloidosis will follow. Pocket guides are available for this topic.
ASH is developing guidelines for aplastic anemia covering diagnosis, transplant, medical management of immunosuppressive therapies for adult and pediatric populations.
Guidelines covering second-line therapies for ITP in adult populations. These guidelines will update and augment ASH ITP guidelines for adult and pediatric populations that were published in 2019. Pocket guides are available for this topic.
Guidelines to address management of cancer-related anemia, in collaboration with the American Society of Clinical Oncology (ASCO) were published in 2019.
Five ASH Sickle Cell Disease Guidelines covering cardiopulmonary and kidney disease, cerebrovascular disease, transfusion, transplantation, and pain management, were published between 2014 and 2021. Pocket guides are available for this topic.
Ten guidelines covering prophylaxis for medical patients, diagnosis, anticoagulation therapy, heparin-induced thrombocytopenia, pregnancy, pediatrics, treatment, cancer, thrombophilia, prophylaxis in surgical patients, and anticoagulation in COVID-19 patients, were published between 2018 and 2025. Pocket guides are available for this topic.
Two guidelines on the diagnosis and management of VWD, in collaboration with the International Society on Thrombosis and Haemostasis (ISTH), National Hemophilia Foundation (NHF), and World Federation of Hemophilia (WFH) were published in 2021. Pocket guides are available for this topic.
Topic Proposals and Public Comment
Guideline Topic Proposal
ASH is currently reviewing its approach to clinical practice guideline development and maintenance, including how topics are identified, prioritized, and updated. During this time, ASH is not accepting new guideline topic proposals.
Proposals already submitted will remain on record as ASH considers future guideline needs and processes.
Public Comment
Draft guidelines for the American Society of Hematology (ASH) are made available for public comment. Draft recommendations and draft evidence-to-decision frameworks are made available, but not full guideline reports.
Anyone is welcome to comment, including ASH members, non-member physicians and researchers, allied professionals, representatives from industry and insurance companies, patients, caregivers, and members of the public.
Questions?
If you have questions, please email [email protected].